Piper Sandler Completes the Acquisition of Stamford Partners LLP, Forming European Consumer Team
Piper Sandler Companies (NYSE: PIPR), a leading investment bank, today announced that it has completed the acquisition of Stamford Partners LLP. The London-based team offers best-in-class M&A advisory services tailored to the unique needs of clients in the European consumer industry, led by the firm’s three partners, Damian Thornton, Simon Milne and Alastair Mathieson. This adds yet another industry-leading advisory practice to the Piper Sandler platform and broadens Piper Sandler’s European investment banking capabilities.
“We are excited to partner with a firm that shares our vision, culture and commitment to clients through their journey. This partnership is in line with our goal to grow our investment banking practice in Europe with teams who share our philosophy and provide leading advisory services and deep sector expertise,” said Peter Hall, managing director and head of European investment banking at Piper Sandler.
Piper Sandler has a leading consumer franchise with over 50 dedicated investment banking professionals. The team specializes in multiple key verticals across the consumer landscape, including agriculture, beauty & personal care, diversified consumer products, food & beverage, health & wellness services, restaurants and retail & disruptive commerce.
About Piper Sandler
As a leading investment bank, we enable growth and success for our clients through deep sector expertise, candid advice and a differentiated, highly productive culture. We transcend transactions to define possibilities—enabling clients to achieve their short-term goals while realizing their long-term vision. Founded in 1895, the firm is headquartered in Minneapolis with offices across the United States and in London, Aberdeen and Hong Kong. Learn more at PiperSandler.com.
Piper Sandler Companies (NYSE: PIPR) is a leading investment bank driven to help clients Realize the Power of Partnership®. Securities brokerage and investment banking services are offered in the U.S. through Piper Sandler & Co., member SIPC and NYSE; in the U.K. through Piper Sandler Ltd., authorized and regulated by the U.K. Financial Conduct Authority; and in Hong Kong through Piper Sandler Hong Kong Ltd., authorized and regulated by the Securities and Futures Commission. Alternative asset management and fixed income advisory services are offered through separately registered advisory affiliates.
Follow Piper Sandler: LinkedIn | Facebook | Twitter
©2022. Since 1895. Piper Sandler Companies. 800 Nicollet Mall, Minneapolis, Minnesota 55402-7036
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220613005159/en/
Contact information
Pamela Steensland
Tel: 612 303-8185
pamela.steensland@psc.com
Tim Carter
Chief Financial Officer
Tel: 612 303-5607
timothy.carter@psc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Polpharma Biologics and Libbs Farmacêutica Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases10.12.2025 08:01:00 EET | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, is thrilled to announce the signing of a landmark licensing agreement with the Brazilian company Libbs Farmacêutica! Through this strategic partnership, Libbs Farmacêutica will gain exclusive rights to commercialize a cutting-edge biosimilar for autoimmune diseases in the rapidly growing Brazilian market. Polpharma Biologics retains full responsibility for the development and manufacturing of the biosimilar. Libbs Farmacêutica will hold an exclusive license for the commercialization, marketing and distribution of the biosimilar in Brazil. This collaboration opens up exciting new opportunities and demonstrates the shared commitment of both companies to delivering innovative and accessible therapies to patients. “Entering the Brazilian market with a biosimilar is a significant step for Polpharma Biologics and reflects our ongoing mission to expand access to high-qual
NayaPay Launches Global QR Payments for Pakistanis via Alipay+10.12.2025 06:00:00 EET | Press release
NayaPay, one of Pakistan’s fastest growing fintech platforms, has launched global QR payments in collaboration with Alipay+, Ant International’s global wallet gateway. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209591389/en/ The partnership enables millions of NayaPay users to scan-and-pay at Alipay+ merchants initially across more than 50 countries, connecting Pakistani consumers to an extensive global ecosystem spanning retail, dining, transport, healthcare, entertainment and more. With this innovative feature, paying abroad just got faster and more affordable. With NayaPay, Pakistanis can now scan and pay securely worldwide with lower costs, less friction, and a seamless checkout experience wherever they go. Alipay+ connects 40 international mobile payment partners to more than 150 million merchants globally. The launch reinforces NayaPay’s commitment to delivering world-class payment experiences to Pakistani consu
Biocytogen Completes STAR Market IPO, Becoming the First “H+A” Global Drug Innovator10.12.2025 04:50:00 EET | Press release
Biocytogen (Beijing) Pharmaceutical Technology Co., Ltd. (“Biocytogen,” SSE: 688796; HKEX: 02315), a global biotechnology company advancing innovative drug discovery, today announced its successful listing on the Shanghai Stock Exchange STAR Market. This follows the Company’s listing on the Hong Kong Stock Exchange in September 2022 and marks a significant milestone in establishing Biocytogen as the first “H+A” dual-listed global drug innovator, reinforcing its mission to become the global headstream of new drugs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209977992/en/ The Company’s IPO price was set at 26.68 RMB per share, with an opening price of 58 RMB, representing a 117% increase over the offering price. Based on the opening price, Biocytogen’s market capitalization exceeds 25.9 billion RMB. Biocytogen’s proprietary RenMice® platforms (RenMab™, RenLite®, RenNano®, RenTCR-mimic™) enable the discovery of fully hum
Argo Infrastructure Partners Increases Ownership and Capital Commitment to TierPoint10.12.2025 00:00:00 EET | Press release
Argo Infrastructure Partners, LP (“Argo”), an established mid-market asset manager of essential infrastructure assets in North America, today announced it has acquired on behalf of its managed funds the equity interests of the majority of minority shareholders in TierPoint. The transaction reflects Argo’s continued conviction in TierPoint’s strategy and growth potential during a period of accelerating demand for TierPoint’s enterprise-class data center services. Since Argo’s initial investment in 2020, $3 billion of capital has been raised to fund growth and reduce TierPoint’s cost of capital by terming out debt facilities. The investment capital has advanced TierPoint’s market position as a data center services provider to enterprises, government organizations, hyperscalers and other consumers of state-of-the-art digital infrastructure. With these investments, Argo has supported the national expansion of TierPoint’s data center platform, and its efforts to meet and exceed customers’ r
Venture Global Announces Closing of $3,000,000,000 Senior Secured Notes by Venture Global Plaquemines LNG, LLC9.12.2025 23:30:00 EET | Press release
Venture Global, Inc. (“Venture Global”, NYSE: VG) announced today that its subsidiary, Venture Global Plaquemines LNG, LLC (“VGPL”) has closed an offering of $3,000,000,000 aggregate principal amount of senior secured notes, which has been issued in two series: (i) a series of 6.125% senior secured notes due 2030 in an aggregate principal amount of $1,750,000,000 (the “2030 Notes”) and (ii) a series of 6.500% senior secured notes due 2034 in an aggregate principal amount of $1,250,000,000 (the “2034 Notes” and, together with the 2030 Notes, the “Notes”). The 2030 Notes will mature on December 15, 2030, and the 2034 Notes will mature on June 15, 2034. Venture Global had previously announced the issuance of $2,500,000,000 of senior secured notes by VGPL on April 21, 2025, and $4,000,000,000 of senior secured notes by VGPL on July 3, 2025 (collectively, the “Existing Notes”), bringing the combined aggregate amount of senior secured notes issued by VGPL to $9,500,000,000 since the project
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom